SNIPR Biome further strengthens CRISPR/Cas IP portfolio with patent grant
SNIPR Biome further strengthens CRISPR/Cas IP portfolio with patent grant · Patent issuance adds to SNIPR’s extensive intellectual property portfolio, comprising more than 60 granted worldwide patents, including in the USA and Europe · Patent covers the use of killing of bacteria at least 1000-fold in a microbiome using any CRISPR/Cas system · USPTO has also issued a Notice of Allowance for methods of using CRISPR lytic phage Copenhagen, December 22 2022: SNIPR Biome ApS (“SNIPR” or “the Company”), the company pioneering CRISPR-based microbial gene therapy, announces